Imagen principal (Hero)
Grupo de Trabajo SMD
Estudios (SMD)
No hay elementos para este grupo de trabajo.
Estudios epidemiológicos (SMD)
No hay elementos para este grupo de trabajo.
Otros (SMD)
No hay elementos para este grupo de trabajo.
Eventos Científicos (SMD)
No hay eventos científicos relacionados con el grupo de trabajo.
Publicaciones (SMD)
Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA
Garcia-Gisbert, N; Garcia-Avila, S; Merchan, B; Salido, M; Fernandez-Rodriguez, C; Gibert, J; Fernandez-Ibarrondo, L; Camacho, L; Lafuente, M; Longaron, R; Espinet, B; Velez, P; Pujol, RM; Andrade…
Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosis
Sorigue, M; Arenillas, L; Xicoy, B; Andrade-Campos, M; Navarro, JT; Ferrer, A; Zamora, L; Calvo, X
Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes
Saumell, S; Fernandez-Serrano, M; Mesa, A; Lopez-Cadenas, F; Arenillas, L; Alfonso, A; Montoro, MJ; Molero, A; Leoz, P; Riego, V; Gallur, L; Salamero, O; Navarrete, M; Tazon-Vega, B; Ortega, M; Reig,…
Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia
Martin-Izquierdo, M; Abaigar, M; Hernandez-Sanchez, JM; Tamborero, D; Lopez-Cadenas, F; Ramos, F; Lumbreras, E; Madinaveitia-Ochoa, A; Megido, M; Labrador, J; Sanchez-Real, J; Olivier, C; Davila, J;…
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
Martin, I; Villamon, E; Abellan, R; Calasanz, MJ; Irigoyen, A; Sanz, G; Such, E; Mora, E; Gutierrez, M; Collado, R; Garcia-Serra, R; Vara, M; Blanco, ML; Oiartzabal, I; Alvarez, S; Bernal, T; Granada…
Coexistence of JAK2V617F mutation and isolated del(5q) in a patient with thrombocytosis
A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
Liquori, A; Lesende, I; Palomo, L; Avetisyan, G; Ibanez, M; Gonzalez-Romero, E; Boluda-Navarro, M; Morote-Faubel, M; Garcia-Ruiz, C; Martinez-Valiente, C; Santiago-Balsera, M; Gomez-Segui, I; Sanjuan…
Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach
Acha, P; Palomo, L; Fuster-Tormo, F; Xicoy, B; Mallo, M; Manzanares, A; Grau, J; Marce, S; Granada, I; Rodriguez-Luaces, M; Diez-Campelo, M; Zamora, L; Sole, F
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study
Pleyer, L; Leisch, M; Kourakli, A; Padron, E; Maciejewski, JP; Cirici, BX; Kaivers, J; Ungerstedt, J; Heibl, S; Patiou, P; Hunter, AM; Mora, E; Geissler, K; Dimou, M; Lorenzo, MJJ; Melchardt, T; Egle…
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
Cabezon, M; Malinverni, R; Bargay, J; Xicoy, B; Marce, S; Garrido, A; Tormo, M; Arenillas, L; Coll, R; Borras, J; Jimenez, MJ; Hoyos, M; Valcarcel, D; Escoda, L; Vall-Llovera, F; Garcia, A; Font, LL;…